TSX News -
Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast Cancer
MONTREAL, Sept. 03, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced filing […]